Division of Environmental Toxicology, Chulabhorn Graduate Institute, Bangkok, Thailand; Laboratory of Environmental Toxicology, Chulabhorn Research Institute, Bangkok, Thailand; Center of Excellence on Environmental Health, Toxicology and management of Chemicals, Bangkok, Thailand; Institute for Risk Assessment Sciences, Utrecht University, Utrecht, The Netherlands; Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Thailand.
J Steroid Biochem Mol Biol. 2013 Nov;138:54-62. doi: 10.1016/j.jsbmb.2013.03.007. Epub 2013 Apr 3.
About 70% of breast tumors express androgen receptors. In addition, there is clinical evidence suggesting that androgens can inhibit mammary epithelial proliferation. Vice versa, there is also significant evidence indicating that androgens can increase the risk of breast cancer via multiple mechanisms, e.g. direct conversion to estrogens that can bind to the estrogen receptor and thereby stimulate cell proliferation. We examined the effect of testosterone (T) and dihydroxytestosterone (DHT) on cell proliferation, pS2 and Ki-67 expression in three different breast cancer cell lines alone or in co-culture with primary human breast adipose fibroblasts (BAFs) obtained from breast cancer patients. In the co-cultures, T induced cell proliferation, pS2 and Ki-67 expression in the estrogen receptor positive (ER(+)) MCF-7 and T47D cells. This was not observed in the (ER(-)) MDA-MB-231 cells. The differences might be explained by the high expression of aromatase, which converts androgens to estrogens in BAFs followed by ER-mediated cell proliferation. In line with this absence of increased cell proliferation, pS2 and Ki-67 expression was observed in the presence of DHT, which is not a substrate for aromatase. In contrast, DHT caused a significant suppression of cell proliferation (68% and 38%), pS2 and Ki-67 expression in the (ER(+)) MCF-7 and T47D cells. More importantly, DHT decreased cell proliferation in (ER(-)) MDA-MB-231 cells by 38%. The results suggest that androgens that cannot be aromatized, like DHT, may provide a perspective for treatment of breast cancer patients, especially those with triple negative breast cancer.
约 70%的乳腺肿瘤表达雄激素受体。此外,有临床证据表明,雄激素可以抑制乳腺上皮细胞增殖。反之,也有大量证据表明,雄激素可以通过多种机制增加乳腺癌的风险,例如直接转化为可以与雌激素受体结合并刺激细胞增殖的雌激素。我们研究了雄激素(T)和二羟睾酮(DHT)对三种不同乳腺癌细胞系单独或与从乳腺癌患者获得的原代人乳腺脂肪成纤维细胞(BAFs)共培养时对细胞增殖、pS2 和 Ki-67 表达的影响。在共培养中,T 诱导雌激素受体阳性(ER(+)) MCF-7 和 T47D 细胞的细胞增殖、pS2 和 Ki-67 表达。在(ER(-)) MDA-MB-231 细胞中没有观察到这种情况。这种差异可能是由于 BAF 中高表达的芳香酶将雄激素转化为雌激素,然后通过 ER 介导的细胞增殖来解释。与缺乏增加的细胞增殖一致,在不是芳香酶底物的 DHT 存在下观察到 pS2 和 Ki-67 表达。相比之下,DHT 导致(ER(+)) MCF-7 和 T47D 细胞的细胞增殖(68%和 38%)、pS2 和 Ki-67 表达显著抑制。更重要的是,DHT 使(ER(-)) MDA-MB-231 细胞的细胞增殖减少 38%。结果表明,不能芳香化的雄激素,如 DHT,可能为治疗乳腺癌患者,特别是三阴性乳腺癌患者提供一种新视角。